EQUILLIUM, INC. Lessee, Operating Lease, Liability, to be Paid, Year One
EQUILLIUM, INC. (EQ) had Lessee, Operating Lease, Liability, to be Paid, Year One of $421.00 thousand as of 2025-12-31, per its 10-K filed 2026-03-25.
Financial Statements › Notes › Lessee, Operating Lease, Liability, to be Paid, Fiscal Year Maturity
us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths · last filed 2026-03-25
- 2025-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $421.00K.
- 2024-12-31: Lessee, Operating Lease, Liability, to be Paid, Year One $219.00K.
- 2024-09-30: Lessee, Operating Lease, Liability, to be Paid, Year One $219.00K.
- 2024-06-30: Lessee, Operating Lease, Liability, to be Paid, Year One $219.00K.
| Period end | Lessee, Operating Lease, Liability, to be Paid, Year One |
|---|---|
| 2025-12-31 | $421.00K 10-K · filed 2026-03-25 |
| 2024-12-31 | $219.00K 10-K · filed 2025-03-27 |
| 2024-09-30 | $219.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | $219.00K 10-Q · filed 2024-08-08 |
| 2024-03-31 | $219.00K 10-Q · filed 2024-05-09 |
| 2023-12-31 | $492.00K 10-K · filed 2024-03-25 |
| 2023-09-30 | $492.00K 10-Q · filed 2023-11-08 |
| 2023-06-30 | $492.00K 10-Q · filed 2023-08-09 |
| 2023-03-31 | $492.00K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $494.00K 10-K · filed 2023-03-23 |
| 2022-09-30 | $494.00K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $494.00K 10-Q · filed 2022-08-15 |
| 2022-03-31 | $494.00K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $510.00K 10-K · filed 2022-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Biomea Fusion, Inc. (BMEA) | United States | $0.107B | -3.30 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| OnKure Therapeutics, Inc. (OKUR) | United States | $0.119B | -3.13 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |